Bio-Active Company LIMITED

Bio-Active Company LIMITED, a Thailand-based for-profit limited liability company, supplies genetic sequencing instruments, laboratory reagents, and maintenance services to U.S. federal agencies conducting infectious disease monitoring and research in Southeast Asia, operating exclusively as a prime contractor (100% of awards) with no set-aside designations.

The vendor's capability portfolio centers on Illumina sequencing platforms (MiSeq, NextSeq, NextSeq 2000, Chromium X), associated reagents and consumables for DNA and RNA sequencing, and annual maintenance and emergency support for laboratory equipment. Representative work includes a $504 thousand Department of the Army Blanket Purchase Agreement established September 24, 2026, for maintenance and emergency services on various laboratory instruments across Southeast Asia with a ceiling through September 27, 2031; a $1.98 million Defense Health Agency single-award BPA for commercial laboratory medical supplies and reagents established June 15, 2026; a $168.7 thousand National Institute of Allergy and Infectious Diseases purchase order (March 7, 2022–March 6, 2025) for annual maintenance of an Illumina NextSeq 2000 system in Cambodia; a $223.4 thousand Department of the Army purchase order (September 8, 2025) for Illumina MiSeq and NextSeq platforms supporting DNA and RNA sequencing of clinical, environmental, and vector-borne disease samples at the Armed Forces Research Institute of Medical Sciences (AFRIMS) Thailand; and a $177.9 thousand Department of the Army purchase order (July 11, 2023) for virus-detection reagents (influenza, dengue, chikungunya, SARS-CoV-2) supplied to CDC Thailand.

Customer concentration skews toward defense and civilian health agencies with operations in Southeast Asia. The top five funding agencies by award count account for 75% of recent awards: Department of the Army Medical Command (17 awards, $320 thousand), Department of State Bureau of East Asian and Pacific Affairs (13 awards, $373 thousand), Department of the Army (11 awards, $1.6 million), CDC Pittsburgh (9 awards, $316 thousand), and Department of the Navy Bureau of Medicine and Surgery (7 awards, $724 thousand). The potential-value ranking diverges significantly: Defense Health Agency anchors 81% of combined potential value ($2.3 million across 3 awards), while Department of the Army ranks second ($1.6 million across 11 awards). This split reflects the $1.98 million Defense Health Agency BPA established in June 2026, which substantially outweighs the vendor's historical per-award values of $27 thousand to $178 thousand.

Bio-Active operates under two active Blanket Purchase Agreements: Department of the Army BPA 19GE5021A0003 (8 task orders, $245 thousand combined value, through September 27, 2031) and Department of State Bureau of East Asian and Pacific Affairs BPA 19GE5026A0086 (1 task order, $92 thousand, through August 16, 2026). The vendor holds a prior single-award BPA with Department of Defense Medical Command (May 1, 2021) that historically generated task orders of $26 thousand to $29 thousand and serves as an umbrella vehicle through which multiple civilian and defense agencies issue orders for sequencing instrument maintenance and support.

Award activity has averaged 6.2 awards annually over the past five years (2022–2026), with recent years showing 8, 5, 4, 7, and 6 awards respectively. Three awards with ultimate completion dates within the next twenty-four months carry combined potential value of $354 thousand, creating modest recompete exposure. The vendor's work concentrates in Analytical Laboratory Instrument Manufacturing (22 awards), Other Electronic and Precision Equipment Repair and Maintenance (14 awards), and Medical Laboratories (8 awards) NAICS categories, with PSC coding reflecting Laboratory Equipment and Supplies (34 awards) and Medical and Surgical Instruments and Supplies (17 awards). Place of performance spans Thailand and Cambodia, with primary operational footprint at AFRIMS Bangkok and NIAID facilities in Phnom Penh supporting U.S. government disease surveillance and research operations in the Indo-Pacific region.